13 valent pneumococcal conjugate vaccine

BIOLOGICAL7 trials

Conditions

Healthy SubjectsInfectious DiseasesInfluenzaPneumococcal InfectionsPneumococcal VaccinesPneumococcal acquisition and vaccine immunogenicityVaccines, Pneumococcal

Phase 2

Baby Vaccine Study (Sched3)

CompletedNCT02482636

University of OxfordInfectious Diseases

Start: 2015-08-31End: 2021-06-30Updated: 2021-09-20

Phase 3

Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine

CompletedNCT00373958

PfizerVaccines, Pneumococcal

Start: 2006-09-30End: 2008-06-30Updated: 2013-02-21

Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine

CompletedNCT00521586

PfizerInfluenza

Start: 2007-09-30End: 2013-12-31Updated: 2015-04-09

Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

CompletedNCT00546572

Wyeth is now a wholly owned subsidiary of PfizerPneumococcal Infections

Start: 2007-11-30End: 2010-07-31Updated: 2011-07-14

Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS

CompletedNCT00574548

Wyeth is now a wholly owned subsidiary of PfizerPneumococcal Vaccines

Start: 2007-11-30End: 2010-02-28Updated: 2011-07-22

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years

CompletedNCT00761631

PfizerHealthy Subjects

Start: 2008-12-31End: 2010-07-31Updated: 2013-07-31

Phase 4

Pneumococcal Vaccine Schedules Acquisition-Immunogenicity

RecruitingPACTR202105670402672

London School of Hygiene and Tropical MedicinePneumococcal acquisition and vaccine immunogenicity

Start: 2020-07-01Target: 784Updated: 2026-01-27

Related Papers

Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial.

2021-01-085 citations

Understanding the reactogenicity of 4CMenB vaccine: Comparison of a novel and conventional method of assessing post-immunisation fever and correlation with pre-release in vitro pyrogen testing.

2020-10-24

Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial.

2017-11-2291 citations

Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.

2016-05-0521 citations

Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.

2014-03-05114 citations